ALK and diffuse large B-cell lymphoma: The strongest factor associated to survival in ALK-DLBCL cases from the literature was clinical stage at presentation; patients with advanced stages had a median survival of 18 months while patients with earlier stages have not reached their median survival (Figure 6).